🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

210 results for “Ovid” Clear

  1. Placebo to Remdesivir - Saline, Remdesivir, PF-07817883 Tablet, Placebo to Ibuzatrelvir

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Coronavirus Disease 2019 (COVID-19)

    phase 3 small molecule active

    1 trial

  2. Placebo will be provided in size and appearance identical to those containing milsaperidone and will be administered orally., Milsaperidone, Milsaperidone, Milsaperidone

    Vanda Pharmaceuticals Netherlands B.V.

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  3. Pomalidomide, Imnovid 3 mg hard capsules, Imnovid 1 mg hard capsules, Imnovid 2 mg hard capsules, Imnovid 4 mg hard capsules, Pomalidomide, Pomalidomide, DARZALEX 1800 mg solution for injection, Imnovid 3 mg hard capsules, BORTEZOMIB, Imnovid 2 mg hard capsules, FLUDARABINE , CARVYKTI 3.2 × 10^6 – 1.0 × 10^8 cells dispersion for infusion, Pomalidomide, Imnovid 4 mg hard capsules, Dexamethasone Tablets BP 2.0mg, Fortecortin® 2 mg Tabletten, Imnovid 1 mg hard capsules, CYCLOPHOSPHAMIDE , Dexamethason 4 mg JEN

    Janssen-Cilag International N.V.

    Relapsed and Lenalidomide-Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  4. Privigen 100 mg/ml solution for infusion, Fortecortin® 2 mg Tabletten, Dexamethason 8 mg GALEN® Tabletten, Privigen 100 mg/ml solution for infusion, teclistamab, JNJ-64407564, Pomalidomide, Dexamethasone Tablets BP 2.0mg, Imnovid 3 mg hard capsules, Pomalidomide, Imnovid 1 mg hard capsules, Empliciti 400 mg powder for concentrate for solution for infusion., Empliciti 300 mg powder for concentrate for solution for infusion., Pomalidomide, VELCADE 3.5 mg powder for solution for injection, Privigen 100 mg/ml s

    Janssen-Cilag International N.V.

    Relapsed or Refractory Myeloma

    phase 3 small molecule active

    1 trial

  5. RO7496998

    Atea Pharmaceuticals

    COVID-19

    phase 3 small molecule terminated

    1 trial

  6. Recommended treatment schedule

    Prime Medicine

    COVID-19

    phase 3 small molecule terminated

    1 trial

  7. Remdesivir

    First Tracks Biotherapeutics

    Covid19

    phase 3 small molecule active

    1 trial

  8. Rozlytrek, Rozlytrek, RO 743-5846/F06, Ipatasertib, Rozlytrek, INAVOLISIB, Ipatasertib, INAVOLISIB, RO7538483, Rozlytrek 200 mg hard capsules, Rozlytrek 100 mg hard capsules, Avastin 25 mg/ml concentrate for solution for infusion., Tiragolumab, RO 743-5846/F04, Tecentriq 1 200 mg concentrate for solution for infusion, ABIRATERONE

    Roche Registration Limited

    This is an extension study designed to provide continued treatment for eligible patients with cancer who were previously enrolled and treated in a Genentech/Roche study (the parent study), and do not have access to the treatment locally

    phase 3 small molecule active

    1 trial

  9. SARS-CoV-2 Vaccine (Vero Cell), Inactivated

    China SXT Pharmaceuticals

    COVID-19 Pneumonia

    phase 3 mab completed

    1 trial

  10. SARS-CoV-2 inactivated vaccine

    SINOVAC BIOTECH LTD

    Covid19

    phase 3 mab completed

    1 trial

  11. SOC plus 15mg/kg EB05 IV

    Edesa Biotech

    COVID-19

    phase 3 mab on hold

    1 trial

  12. Sarilumab

    Regeneron UK Limited

    COVID-19

    phase 3 small molecule completed

    1 trial

  13. Sipavibart, SODIUM CHLORIDE, EVUSHELD 150 mg + 150 mg solution for injection, EVUSHELD 150 mg + 150 mg solution for injection

    AstraZeneca AB

    COVID-19

    phase 3 small molecule active

    1 trial

  14. TAK-019

    Takeda Pharmaceuticals International AG

    Coronavirus Disease (COVID-19)

    phase 3 mab completed

    1 trial

  15. TIRBANIBULIN, Placebo of the new presentation of 350 mg/sachet drug product (hereafter referred as vehicle) is a smooth, creamy white to off-white ointment free from foreign particles, packed intact and properly sealed containing the same qualitative composition as the active product but without the active substance. The vehicle will be provided in a single-use packets to contain 350 mg of drug product., Klisyri 10 mg/g ointment

    Almirall

    Actinic Keratosis on the Face or Scalp

    phase 3 small molecule active

    1 trial

  16. Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine

    United Therapeutics Europe Ltd

    COVID-19

    phase 3 small molecule terminated

    1 trial

  17. Traditional Chinese Medicine Prescription

    China SXT Pharmaceuticals

    COVID-19

    phase 3 small molecule active

    1 trial

  18. Trivalent COVID-19 Vaccine (Vero Cell), Inactivated, Prototype Strain, Delta Strain and Omicron Strain

    SINOVAC BIOTECH LTD

    COVID-19

    phase 3 mab active

    1 trial

  19. Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14

    SINOVAC BIOTECH LTD

    Covid19

    phase 3 mab completed

    1 trial

  20. VIR-7831

    Vir Biotechnology

    COVID-19

    phase 3 mab completed

    1 trial

  21. VIR-7831 (sotrovimab)

    Vir Biotechnology

    Covid19

    phase 3 mab completed

    1 trial

  22. Yinhu Qingwen Granula

    China SXT Pharmaceuticals

    COVID-19

    phase 3 small molecule on hold

    1 trial

  23. alpha1-proteinase inhibitor

    Takeda Pharmaceuticals International AG

    Covid19

    phase 3 small molecule terminated

    1 trial

  24. casirivimab+imdevimab combination therapy

    Regeneron UK Limited

    COVID-19

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources